Empagliflozin

Catalog No. A12440

Empagliflozin是一种有效的选择性葡萄糖钠共转运蛋白-2抑制剂，目前正在开发中，用于治疗2型糖尿病。

Product Citations

Yu-Jung Heo, .et al. Empagliflozin Reduces the Progression of Hepatic Fibrosis in a Mouse Model and Inhibits the Activation of Hepatic Stellate Cells via the Hippo Signalling Pathway, Biomedicines, 2022, Apr 29;10(5):1032 PMID: 35625768
Nami Lee, .et al. Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF- κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways, J Immunol Res, 2021, Jun 2;2021:9944880 PMID: 34124273
CN Koyani, .et al. Empagliflozin Protects Heart From Inflammation and Energy Depletion via AMPK Activation, Pharmacol Res, 2020, May 17;158:104870 PMID: 32434052

Technical details

Catalog Num	A12440
M. Wt	450.91
Formula	C23H27ClO7
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	864070-44-0
Synonyms
SMILES	C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl

Biological Activity

Empagliflozin是一种有效的选择性葡萄糖钠共转运蛋白-2抑制剂，目前正在开发中，用于治疗2型糖尿病。

Targets

SGLT2	SGLT5	SGLT6	SGLT1	SGLT4
3.1 nM	1.1 μM	2 μM	8.3 μM	11 μM

Solubility *

In vitro (25°C)	DMSO	88 mg/mL (195.15 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	15% Captisol	14 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	22.18 mL	110.89 mL	221.77 mL
0.5 mM	4.44 mL	22.18 mL	44.35 mL
1 mM	2.22 mL	11.09 mL	22.18 mL
5 mM	0.44 mL	2.22 mL	4.44 mL

*The above data is based on the productmolecular weight 450.91. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.